key: cord-312178-tojgojjf authors: Segars, James; Katler, Quinton; McQueen, Dana B.; Kotlyar, Alexander; Glenn, Tanya; Knight, Zac; Feinberg, Eve C.; Taylor, Hugh S.; Toner, James P.; Kawwass, Jennifer F. title: Prior and Novel Coronaviruses, COVID-19, and Human Reproduction: What Is Known? date: 2020-04-16 journal: Fertil Steril DOI: 10.1016/j.fertnstert.2020.04.025 sha: doc_id: 312178 cord_uid: tojgojjf Structured Abstract Objective To summarize current understanding of the effects of novel and prior coronaviruses on human reproduction, specifically male and female gametes, and in pregnancy. Design Review of English publications in PubMed and Embase to April 6, 2020. Methods Manuscripts were screened for reports including coronavirus, reproduction, including pathophysiology and pregnancy. Intervention(s) None. Main Outcome Measure(s) Reproductive outcomes; effects on gametes; pregnancy outcomes; neonatal complications. Results Seventy-nine reports formed the basis of the review. Coronavirus binding to cells involves the S1 domain of the spike protein to receptors present in reproductive tissues, including angiotensin converting enzyme-2 (ACE2), CD26, Ezrin, and cyclophilins. SARS-CoV-1 may cause severe orchitis leading to germ cell destruction in males. Reports indicate decreased sperm concentration and motility for 72-90 days following COVID-19 infection. Gonadotropin-dependent expression of ACE2 was found in human ovaries, but it is unclear whether SARS-CoV-2 adversely affects female gametogenesis. Evidence suggests that COVID-19 infection has a lower maternal case fatality rate than SARS or MERS, but anecdotal reports suggest that infected, asymptomatic women may develop respiratory symptoms postpartum. COVID-19 infections in pregnancy are associated with preterm delivery. Postpartum neonatal transmission from mother to child has been reported. Conclusion COVID-19 infection may adversely affect some pregnant women and their offspring. Additional studies are needed to assess effects of SARS-CoV-2 infection on male and female fertility. The rapid spread of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to a pandemic of Coronavirus Disease 2019 (COVID-19) across the globe. As of April 8, 2020 , there are over 1.4 million cases and 86,000 deaths attributed to the virus worldwide. As a result, nations have implemented suppression and mitigation strategies to control community spread, including mandated social distancing, restrictions to non-urgent medical care, and closure of non-essential businesses. Despite these efforts, the spread of SARS-CoV-2 is ongoing, creating a public health crisis and impacting the population world-wide. Coronaviruses are a group of viruses that can cross species barriers and become human pathogens. All seven identified human coronaviruses originated from animal reservoirs including domestic animals, bats, or mice. While most human coronaviruses cause mild illness, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and the novel SARS-CoV-2 have been associated with severe lower respiratory tract infections, acute respiratory distress syndrome, and death (1). The novel SARS-CoV-2 virus spreads rapidly, with 2-3 people infected from every index case, a reproduction number (R 0 ) or transmission rate of 2.24 -3.58 (2) . In contrast, the 2009 H1N1 seasonal influenza had an R 0 of 1.46-1. 48 . The incubation period for SARS-CoV-2 ranges from 2-14 days, and asymptomatic spread occurs prior to onset of symptoms (3, 4) . Transmission is thought to be mainly through respiratory droplets and fomites (5) . In one experiment, viable virus was detected in aerosols for up to three hours, with an estimated half-life of 1.1 hours. In addition, virus was detected on surfaces for days after application, with viable SARS-CoV-2 identified on plastic and stainless steel up to 72 hours (6). SARS-CoV-2 RNA has also been detected in blood and stool and it is not yet known whether the infection can be acquired through exposure to non-respiratory bodily fluids (7) . Symptoms of SARS-CoV-2 infection include fever, cough, fatigue, shortness of breath, sputum production, headache and myalgias. In addition, patients may report gastrointestinal symptoms (8) or anosmia. The severity of infection ranges from asymptomatic carriers, to mild flu-like disease, to critical illness and death. Critically-ill patients may experience respiratory failure, shock or multiorgan dysfunction. Approximately 80% of infections are mild with flu-like symptoms, 15-20% are severe, requiring hospitalization and supplemental oxygen, and 5% are critical and require mechanical ventilation (9). Risk factors for severe illness include age and underlying medical comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension and cancer (10) . Death may occur in up to 3% of infections. Death from SARS-CoV-2 is more common in individuals over age 60 or with underlying medical issues but can occur in younger persons, perhaps related to the inoculum. Associated cardiac arrhythmias may be fatal. While persons of advanced age are most likely to experience severe symptoms, women of reproductive age are also at risk for development of severe disease and death. Furthermore, reproductive age women can act as asymptomatic carriers and increase viral transmission. The aim of this review is to summarize what is currently known about the impact of prior coronaviruses and the novel SARS-CoV-2 infection on reproduction and pregnancy. A systematic search in the literature published in the PubMed and Embase databases was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Literature review of available literature in English, both published and peer-reviewed on-line publications from 1996-April 6, 2020. Additional sources were identified from citations of retrieved literature. Search strategy for the PubMed and Embase searches is shown below. There was no limitation on sample size. Published reports of experiences with the SARS-CoV-2 virus have increased greatly in the past months, but no randomized trials to date regarding possible treatments were identified. Most reports pertaining to reproduction or pregnancy involved small cohorts, case reports, guidelines, and editorials. Similarly, prior publications of other coronaviruses were limited in number. We reviewed all titles for eligibility. All reports including pregnancy or reproductive tissues were included. We excluded editorials and publications of guidelines. We excluded papers that were duplicates or did not contain information related to pregnancy or reproduction, the presence of virus in reproductive tissues, effects on gametes, pregnancy outcomes, or neonatal complications. Case reports were included. Because of the limited nature of the reports and the absence of randomized trials we did not use the Cochrane RoB 2.0 tool. Similarly, because of the limited scope of the cohort studies, we did not use the Newcastle-Ottawa Scale to rate the studies. Full text articles were then reviewed and evaluated for inclusion by authorship teams. Two independent reviewers (J.S. and Z.K.) Any disagreements were resolved through discussion with third reviewer (J.K.). The authors acknowledge the number of publications about the novel SARS-CoV-2 virus is increasing at an exponential rate and there may be bias toward reporting of positive findings. We used a broad inclusive search strategy so as not to miss a seminal contribution. The The search revealed 663 manuscripts after removal of duplicates. Ninety-seven manuscripts related to pregnancy and coronavirus and only 7 were related to embryos or early reproduction. Small cohorts, case reports, comments on guidelines, guidelines, editorials were retrieved. After exclusion, 79 manuscripts were included in the review based on relevance and new data. A review of the coronavirus structure and function help to inform us on the pathophysiology of coronavirus infectivity. Coronaviruses are large, single-stranded, enveloped RNA viruses approximately 32KB (11) . The viral RNA genome is housed inside a nucleocapsid, which itself is contained within a viral envelope (12) . This envelope comprises three distinct proteins: a "membrane protein" and "envelope protein," which are both directly responsible for viral assembly, as well as a "spike protein," which mediates viral entry into host cells (12) . When viewed with electron microscopy, these spike proteins are surface-exposed markers that produce a recognizable "crown-like" appearance to the virus. The spike proteins serve a critical step in initiating human infection, as well as determining host tissue specificity and inducing host immune response (13) (14) (15) . The coronavirus spike protein is composed of two unique subunits that facilitate viral-host binding (16) (17) (18) (19) . The S1 domain of the spike protein functions in viral binding and attachment to the host cell membrane. Numerous receptors on the human cell membrane that are involved in S1 subunit binding have been identified to date, including angiotensin converting enzyme-2 (ACE2), CD26, Ezrin, and cyclophilins (20, 21) . The S2 domain of the spike protein is responsible for fusion of the viral and host cell membranes, allowing the SARS-CoV-2 viral genome to enter the host cell. This process involves a complex interaction between viral and host machinery, which culminates in rapid viral replication within target cells. International research efforts are currently underway aimed at using the S1 domain of the spike protein as a target for therapeutic anti-viral therapy, as well as vaccine development. The involvement of SARS-CoV-2 infection within human male and female reproductive systems has yet to be fully elucidated. However, results from other coronavirus subtypes, specifically SARS-CoV, help inform knowledge of tissue-specific viral pathophysiology. Current data suggest that the female reproductive system may be spared from viral infection. Immunohistochemical and in situ hybridization studies on tissues from a small cohort of deceased patients that were infected with SARS-CoV failed to identify SARS-CoV viral RNA within the female reproductive tract, including both ovarian and uterine tissue (22) , though ACE2 receptors can be found there. Importantly, there is evidence to suggest that coronavirus infection may impact the male reproductive tract. The ACE2 protein, a main receptor for coronavirus viral entry, is selectively expressed by Leydig cells of the adult testes (23) . There are numerous reports of male reproductive injury after SARS-CoV infection. Leading theories postulate that this is an immune-mediated response to infection since direct inoculation of the coronavirus RNA within testicular tissue has not been described. In a 2005 study of eight postmortem SARS-CoV patients, testicular tissue contained focal atrophy despite lacking identifiable SARS viral RNA (24) . Accordingly, there have been reported cases of SARS-CoV causing severe orchitis, as evidenced by extensive IgG precipitation in testicular interstitial tissue causing germ cell destruction and widespread testicular leukocyte infiltration (25) . Further studies on the reproductive involvement of coronavirus infections are warranted, particularly within recovered patients. There are limited data regarding the impact of SARS-CoV-2 on human reproduction as the virus is novel and has only recently infected humans. To date, there have been no reports of the virus in the female reproductive tract, in vaginal secretions, in amniotic fluid or in peritoneal fluid. Although there is nothing to suggest that female or male gametes would be impacted directly by infection with SARS-CoV-2 or other coronaviruses, there is evidence that fever can impact spermatogenesis. Therefore, male fertility may be diminished for 72-90 days following COVID-19 due to decreased sperm concentration and motility (26, 27) . The SARS-CoV-2 virus utilizes ACE2 receptors to gain entry into the human cells. The male reproductive system expresses ACE2 within adult Leydig cells in the testis and there are data to suggest that ACE2 plays a role in spermatogenesis. The presence of ACE2 receptors is much more prominent in the male reproductive system than the female reproductive system, but gonadotropin-dependent expression of ACE2 has been reported in human ovaries (28, 29) . At this time, it is unknown if the SARS-CoV-2 virus utilizes ACE2 receptors in the reproductive system and what, if any, impact this would have on oocyte quality, embryo development, or ensuing pregnancy. Gametes obtained from patients with other viral illnesses, such as HIV and hepatitis, must be treated with special precautions aimed at reducing exposure of the non-infected partner and cross contamination of reproductive tissue within the laboratory (30) . These precautions are not currently recommended for SARS-CoV-2, given the lack of evidence for transmission through blood or sexual contact (31) . Similarly, there is no current recommendation for screening oocyte or sperm donors for SARS-CoV-2. These are areas in which further investigation is necessary in order to assure the safety of stored gametes and the safety of patients undergoing assisted reproduction. The case fatality rate for all reported cases of SARS in pregnancy (n=17) was 15% (32-37), and was higher among pregnant women. Mechanical ventilation was required three times more often in pregnant versus non-pregnant women. A case control study comparing ten pregnant to forty non-pregnant women affected by SARS reported a 60% ICU admission rate and a 40% case fatality rate (CFR) in the pregnant group compared to only an 18% and 0% rate in the nonpregnant group (32). Four of seven pregnant patients with SARS miscarried in the first trimester (37) . Four of five women infected after 24 weeks gestation were delivered prematurely, largely due to their deteriorating maternal condition from SARS, at 26, 28 and 32 weeks gestation (38) . The infants born at 26 and 28 weeks developed RDS requiring surfactant, but were normal weight for gestational age. However, among infants born weeks (5 to 7) after initial infection, fetal growth restriction and fibrin deposition on placental interface was seen in two of three pregnancies, suggesting compromise. There was no evidence of vertical transmission. Overall, SARS was a very serious disease for pregnant women and their fetuses. Among pregnant patients with MERS (n=12), 63% were admitted to the ICU (7/11) and three died (CFR of 23%) (39) (40) (41) (42) (43) . The only woman known to contract MERS in the first trimester went on to deliver a healthy infant at term (44) . Of those contracting the disease after the first trimester (n=9), one had a spontaneous loss at 20 week gestation (45) , one presented at 34 weeks gestation with pre-eclampsia and had an intrauterine fetal demise (40) , and a third with preexisting respiratory issues developed MERS at 24 weeks gestation and then ARDS. Despite ventilation and cesarean delivery, both the neonate and mother subsequently died (40) . Three of nine other patients were delivered preterm due to maternal hypoxia. MERS also had a high fatality rate and premature delivery rate. Through April 5, 2020, there have been 19 case reports or series and 2 case-control reports of intrauterine growth restriction (IUGR), 13 were delivered prematurely, 12 were small for gestational age (SGA) and 1 was large for gestational age (LGA). One stillbirth and one neonatal death were reported. Table 2 summarizes the pregnancy-related experience of the three coronavirus epidemics. Peerreviewed case reports to date suggest the following: • COVID-19 has a lower maternal case fatality rate than either SARS or MERS. • Pregnant patients display similar signs and symptoms of COVID-19 as non-pregnant patients. • Pregnant patients are not more susceptible to coronavirus infection, nor at higher risk for severe illness. • Severe illness may precipitate premature labor or lead to early delivery. • Adverse infant outcomes have been reported, but it is unclear whether these outcomes are directly related to COVID-19 infection. Given the teratogenicity concerns associated with viruses such as Zika, there remains the However, a recent case report in JAMA (50) suggests that vertical transmission may be possible. In this case report, an otherwise healthy infant was born by cesarean section to a 29-year-old with RT-PCR confirmed SARS-CoV-2 infection. This infant was immediately placed into isolation and a blood sample at two hours of age was noted to show an elevated SARS-CoV-2 IgG. While the IgG can be secondary to transplacental transfer, the infant was also positive for SARS-CoV-2 IgM which cannot be explained by maternal-fetal transfer (50) . Furthermore, IgM antibodies only appear three-to-seven days after infection. All five RT-PCR tests on the infant were negative for SARS-CoV-2 (50). The antibody profile of this infant is suggestive of exposure to SARS-CoV-2 in-utero. A follow-up study done on six infants born to COVID-19positive mothers showed positive IgM antibodies in two of them. Yet, all throat swabs and blood samples from the neonates tested negative for the virus. Overall, evidence of vertical transmission in the setting of COVID-19 infection is currently inconclusive. Continued observation is necessary as more data is gathered during the course of this pandemic. As of March 31, 2020, there were no identified vaccines or targeted therapies for the treatment of COVID-19. Currently, treatment is aimed at supportive methods such as oxygenation/mechanical ventilation and treating complications. As no effective treatment has been identified, a barrage of potential therapies are being trialed both within and outside of research protocols. Although this list is ever-changing, the majority of these medications target the ability of the virus to replicate or are designed to suppress or modulate the immune system, thereby limiting inflammatory damage (67, 68) . During pregnancy these potential remedies fall into three different departments: those established to be safe in pregnancy, those with unknown status, and those which have clear or relative contraindications during pregnancy. It is imperative to consider that although some of these interventions are safe in pregnancy, none so far have been identified as definitive treatment and all have potential risks. These concerns need to be considered as an additional risk assumed by pregnant women; some potential therapies may carry risk to the fetus or be unavailable to pregnant women. Several investigated medical treatments for COVID-19 are known either to be safe or nonteratogenic in pregnancy. These include various immune modulators such as hydroxychloroquine/chloroquine, methylprednisolone/glucocorticoids, and the anti-viral medications lopinavir-ritonavir (69) (70) (71) (72) (73) . It is important to note that although non-teratogenic, the use of glucocorticoids in pregnancy has been associated with diabetes, weight gain, preterm premature rupture of membranes, hypertension, and intrauterine growth restriction. Interferon therapy, often used in Hepatitis C treatment, has been well established to be safe in pregnancy (74) . The use of convalescent plasma, or plasma derived from individuals who previously contracted COVID-19, has been shown to reduce disease sequela in those with severe disease (75) . Given that its risk profile should be similar to a blood transfusion, there are no overt contraindications in pregnancy. East respiratory syndrome coronavirus in monkeys (76) . Although current clinical studies exclude pregnant women, Remdesivir may be administered in critically-ill pregnant patients (NCT0428070500) (77) . To date, no information is available concerning the effects of Remdesivir in pregnancy. Due to the increased release of cytokines and subsequent inflammatory damage during COVID-19, Tocilizumab, a monoclonal antibody that binds the receptor IL-6, has been used in China, with at least one clinical trial that is ongoing (NCT04310228) (78, 79) . A major concern for pregnant patients is that IgG isotype antibodies cross the placenta at an increasing rate in accordance with gestational age (79) . However, the effect of each medication on fetal development is unknown. Furthermore, in the rheumatology literature it is recommended that Tocilizumab be avoided during pregnancy given the lack of data on adverse fetal effects (80) . Other anti-viral medications which have been utilized that have clear evidence of teratogenicity, either in humans or animal models, include Favipiravir and Ribavirin (68, 81, 82) . Notably, the aforementioned medications are experimental, thus it is imperative to have a risk-benefit discussion with patients given the medication side-effect profiles, potential effects in pregnancy, and unknown benefits. Until randomized trials with adequate controls are completed, it is difficult to draw definitive conclusions concerning the efficacy of any of these treatments (71) . Thus far, there has been no indication that infants born to COVID-19 positive mothers experience any significant morbidity or mortality. In the aforementioned case series of nine COVID-19-positive patients who underwent cesarean section, all of their infants had negative COVID-19 testing and had 1-min Apgar scores of 8-9 and 5-min Apgar scores of 9-10. In addition, none of the infants in this series experienced asphyxia or neonatal death (47) . Three newborns have been confirmed with COVID-19 and their infection was likely secondary to exposure to infected caregivers. All three neonates experienced either fever, cough, or vomiting, then subsequently recovered with no severe sequelae (67) . Given the disease course seen in older children, the disease severity can be expected to be worse for neonates with pre-existing cardiac or pulmonary conditions such as congenital heart disease (67). There are a significant number of unknowns concerning COVID-19 and pregnancy, especially regarding the infectivity of a pregnant woman. Therefore, the majority of data are extrapolated from previous experience with other coronaviruses, SARS-CoV and MERS-CoV, as well as influenza pandemics such as the 1918 flu and the Asian flu in the late 1950s (35, 83) . However, pregnant women are not more likely than non-pregnant woman to become infected with SARS-CoV-2, based on data from regions with the first COVID-19 exposures and from previous pandemics (84) . Nor do pregnant women appear to suffer a more severe disease course or higher mortality rate compared to non-pregnant women of a similar age. It has been established that SARS-CoV-2 is spread by respiratory droplets, yet the potential for other routes of transmission, particularly during labor, is unknown (84) . Limited data are available for COVID-19, but it is possible to extrapolate from limited information available on SARS-CoV-2 and other coronaviruses. In the SARS-CoV outbreak, small case reports showed no viral RNA in placental, umbilical cord blood, amniotic fluid, or breastmilk (35, 37, 84) . It is important to note that fecal matter that was aerosolized via the flushing of toilets was noted to spread disease (35) . One could hypothesize that amniotic fluid could become aerosolized and infect others if viral RNA was present through mixing with fecal matter. MERS-CoV had an extremely high death toll, however only twelve cases were documented in pregnancy, and no information is available on viral RNA in pregnancy-specific tissue (35) . To date, there is limited information concerning which fluids in labor could potentially transmit SARS-CoV-2 directly or by aerosolization. While a single maternal vaginal swab in the only suspected case of vertical transmission was negative, it is too early to conclude whether transmission can occur via vaginal secretions (50) . Rectal swabs have not been obtained in pregnant patients; however, a series of ten pediatric patients did confirm SARS-CoV-2 RNA in rectal specimens (85) . Thus, information regarding vaginal deliveries, while limited, remains concerning. As previously noted, case reports have shown no viral RNA in amniotic fluid, cord blood, or breast milk (47) . Until more information is gathered, it is prudent for personnel present during delivery to treat all fluids as potentially contagious and wear appropriate personal protective equipment. On January 7, 2020 thanks to the initial efforts of the late Dr. Jixian Zhang, the SARS-CoV-2 virus was identified as a cause of severe cases of pneumonia that began on December 8 in Wuhan, China. In the first three months of 2020, the novel virus has infected over 1.4 million people and caused more than 87,000 deaths. Declared a pandemic by the WHO on March 11, 2020, the sickness has overwhelmed healthcare resources as it spread. Containment of SARS-CoV-2 has proven exceptionally difficult due to asymptomatic and pre-symptomatic spread of disease, as well as the relatively high person-to-person transmission. As the virus moved from host to host, as is typical of the single-stranded RNA viruses, SARS-CoV-2 has mutated. Notably, there is an enormous phenotypic difference in disease severity from asymptomatic infection to death, but the reasons for this striking variability remains obscure. Despite the overwhelming magnitude of the disease and its worldwide prevalence, information regarding the effects of the novel coronavirus on human reproduction are currently limited. This lack of evidence should not be considered reassuring, since only three months have elapsed since the novel coronavirus jumped species and infected humans. There is reason to be concerned based on data from other coronaviruses. As is typical of this family of viruses, the SARS-CoV-2 spike protein binds the ACE2 receptor, a protein found in many reproductive tissues, including the testis. Of concern, evidence exists that related coronaviruses have caused severe orchitis. While sperm counts can be reduced by high fever alone, the question of other possible long-term effects on male and female gametes is pressing. Specifically, whether there might be shedding of virus in some individuals that might affect the safety and storage of gametes. As noted, evidence continues to emerge regarding effects of the novel coronavirus in pregnancy and some initial reports suggest that complications, particularly after delivery, may be increased. Additional studies are urgently needed. Because of the risk of viral transmission between patients, staff, physicians and providers, and to comply with local restrictions for non-emergency surgeries, many programs of assisted reproduction have suspended procedures throughout the globe during the height of the pandemic. As the assisted reproductive technology (ART) programs resume operations it will be important to gather information regarding the status of individuals infected with the novel coronavirus, and to assess gametes and reproductive outcomes for those who had COVID-19. These studies will be enabled by the availability of serologic testing and more widespread RNA testing for the novel coronavirus. Likewise, researchers should collect data regarding outcomes of pregnancies in women who became infected during pregnancy. While a vaccine may prevent disease, until one is available, information is needed on the safety of medical treatments and outcomes in pregnancy. One limitation of this review is that because of the rapidly increasing number of publications, it is possible that new information may be published contradicting the findings. Because of concern about possible adverse effects, there may be a risk of bias toward reporting positive outcomes. Additionally, since reports have focused on the acuity of treatment, the reproductive effects may be present, but not yet reported. The strength of the report is that our search was comprehensive and conducted, as much as possible, in accordance with PRISMA guidelines. The immense impact of the COVID-19 pandemic in lives lost, healthcare expenses, and economic consequences of countries and individuals is inestimable because the epidemic is still rampant throughout the globe. While data are limited, and incomplete at this time, there is justifiable concern that reproductive consequences of the novel coronavirus may have lasting effects for male reproduction and for some pregnant women and children. Zoonotic origins of human coronaviruses Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Professionals: Frequently Asked Questions and Answers Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis Structure, Function, and Evolution of Coronavirus Spike Proteins Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptorbinding site in spike protein domain A Structural insights into coronavirus entry Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains Ezrin interacts with the SARS coronavirus Spike protein and restrains infection at the entry stage Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis Multiple organ infection and the pathogenesis of SARS Orchitis: a complication of severe acute respiratory syndrome (SARS) History of febrile illness and variation in semen quality Influence of genital heat stress on semen quality in humans Angiotensin-converting enzymes play a dominant role in fertility Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion Patient Management and Clinical Recommendations During the Coronavirus (COVID-19) Pandemic A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome Severe acute respiratory syndrome (SARS) in neonates and children SARS and pregnancy: a case report Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections Infants born to mothers with severe acute respiratory syndrome Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome Impact of Middle East Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome Middle East Respiratory Syndrome Coronavirus Infection During Pregnancy: A Report of 5 Cases From Saudi Arabia MERS-CoV Infection in a Pregnant Woman in Korea Middle East Respiratory Syndrome Coronavirus during Pregnancy Emergency cesarean section in an epidemic of the middle east respiratory syndrome: a case report Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature Stillbirth during infection with Middle East respiratory syndrome coronavirus COVID-19 in pregnancy: early lessons Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia Infants Born to Mothers With a New Coronavirus (COVID-19). In: Front Pediatr Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn Should We Worry? Clin Infect Dis Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study Premature baby in serious condition after coronavirus infection Coronavirus Disease 2019 (COVID-19) During Pregnancy: A Case Serie A case report of neonatal COVID-19 infection in China A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study A pregnant woman with COVID-19 in Central America Antibodies in Infants Born to Mothers With COVID-19 Pneumonia Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia Effects of coronavirus infections in children Middle East respiratory syndrome An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes Coronavirus disease (COVID-19) and neonate: What neonatologist need to know Development of a standard treatment protocol for severe acute respiratory syndrome Immune Modulating Therapies in Pregnancy and Lactation A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States Effects of chloroquine on viral infections: an old drug against today's diseases? A systematic review of the fetal safety of interferon alpha Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Adaptive COVID-19 Treatment Trial (ACTT) Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation Favipiravir as a potential countermeasure against neglected and emerging RNA viruses The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment Pneumonia in pregnancy Interim Considerations for Infection Prevention and Control of Coronavirus Disease 2019 (COVID-19) in Inpatient Obstetric Healthcare Settings COVID-19: faecal-oral transmission? The authors thank Drs. Catherine Racowsky and Dr. Ricardo Azziz.